An article from
Dive Brief
Remission rates observed in a Phase 2 trial fell short of Wall Street’s expectations, though some analysts believe the company should see better results in late-stage testing.
Published Sept. 9, 2026
Getty Images
Tyra disappoints investors with bladder cancer data
Remission rates observed in a Phase 2 trial fell short of Wall Street's expectations, though some analysts believe the company should see better results in late-stage testing.
TL;DRAI
Tyra's dabogratinib showed 57% remission in Phase 2, missing 70% expectations and trailing Zusduri's 78%. The daily pill's safety and subset performance support Phase 3 advancement, but efficacy must match invasive alternatives for market success.
559 words~3 min read
